# A Long-Term Extension Study of AT2101 (Afegostat Tartrate) in Type 1 Gaucher Patients

> **NCT00813865** · PHASE2 · COMPLETED · sponsor: **Amicus Therapeutics** · enrollment: 8 (actual)

## Conditions studied

- Gaucher Disease
- Type 1 Gaucher Disease
- Gaucher Disease, Type 1

## Interventions

- **DRUG:** afegostat tartrate

## Key facts

- **NCT ID:** NCT00813865
- **Lead sponsor:** Amicus Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05-11
- **Primary completion:** 2012-05-01
- **Final completion:** 2012-05-01
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2018-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00813865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00813865, "A Long-Term Extension Study of AT2101 (Afegostat Tartrate) in Type 1 Gaucher Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00813865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*